Epstein Secrets

t has to be repeated over time. Looming on the horizon is the promising CTC circulatory tumor cell microfluidic chip test, a blood test developed at Massachusetts General that can isolate and identify cancer mutations at any given time. To date, the test has identified more than 1,200 cancer-causing genetic mutations,

ound the world. In fact. over the last ten years. the prescription rate of inhibitors over cytotoxic chemotherapy has more than tripled according to the National Institute of Cancer. Indeed in 2004. the Journal of Oncology published a revealing table with cytotoxic chemotherapy as the sole treatment: the 5-year survival rate was

t has to be repeated over time. Looming on the horizon is the promising CTC circulatory tumor cell microfluidic chip test, a blood test developed at Massachusetts General that can isolate and identify cancer mutations at any given time. To date, the test has identified more than 1,200 cancer-causing genetic mutations,

ound the world. In fact. over the last ten years. the prescription rate of inhibitors over cytotoxic chemotherapy has more than tripled according to the National Institute of Cancer. Indeed in 2004. the Journal of Oncology published a revealing table with cytotoxic chemotherapy as the sole treatment: the 5-year survival rate was

t has to be repeated over time. Looming on the horizon is the promising LTC circulatory tumor cell microfluidic chip lest, a blood test developed at Massachusetts General that can Slate and identify cancer mutations at any given time. To date, the test has identified more than 1,200 cancer-causing genetic mutations,

ound the world. In fact, over the last ten years. the prescription rate of inhibitors over cytotoxic chemotherapy has more than tripled according to the National Institute of Cancer. Indeed in 2004. the Journal of Oncology published a revealing table with cytotoxic chemotherapy as the sole treatment: the 5-year survival rate was